
Current Price | $98.74 | Mkt Cap | $9.0B |
---|---|---|---|
Open | $95.87 | P/E Ratio | 18.73 |
Prev. Close | $98.74 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $95.79 - $98.84 | Volume | 801,653 |
52-Wk Range | $65.28 - $103.00 | Avg. Daily Vol. | 668,833 |
The Company is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease.
Current Price | $98.74 | Mkt Cap | $9.0B |
---|---|---|---|
Open | $95.87 | P/E Ratio | 18.73 |
Prev. Close | $98.74 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $95.79 - $98.84 | Volume | 801,653 |
52-Wk Range | $65.28 - $103.00 | Avg. Daily Vol. | 668,833 |
The best Bull and Bear pitches based on recency and number of recommendations.
A long-term experiment to see if riding on Buffett's coattails really gets me anywhere.
Although DaVita has large market share and high pricing power, they have used their semi-monopolistic position in the market to demand high premiums and annual "rate inflators" that keep their rates compounding upwards. Because of this heavy-handed… More
Read the most recent pitches from players about DVA.
Recs
Although DaVita has large market share and high pricing power, they have used their semi-monopolistic position in the market to demand high premiums and annual "rate inflators" that keep their rates compounding upwards. Because of this heavy-handed approach, insurance companies have them on their radar as a high cost provider that the recent slew of consolidations will target for savings. And once one of the big insurance companies gets a rate concession from them, there will be chum in the water and the others will be looking for the same.
Also, they had a pretty simple, stable dialysis business model. With their foray into broader healthcare with HCP, they don't have the expertise or infrastructure to run that more complicated business profitably yet. And with pricing pressure on the Medicare side of things, that business will have to adapt quickly to make them a good return on their investment.
Recs
Expectation of continued growth in demand for their services as the population ages. Greatest risk is a potential drug breakthrough, that would make their services obsolete.
Recs
Company moving to a healthcare model which will deliver primary care to adults with chronic illness such as diabetes and hypertension. This will take them significantly beyond kidney care alone. Although the international division is currently in the red the addition of divisions in China, India, Saudi, and now Latin America is forward thinking.
Find the members with the highest scoring picks in DVA.
TrackJimCramer (< 20) Score: +189.49
The Score Leader is the player with the highest score across all their picks in DVA.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
coolMD | 70.23 | 2/18/2009 |
![]() |
NS | $25.38 | +287.48% | +450.88% | +163.40 | 0 Comment | |
abber24 | 37.12 | 3/25/2008 |
![]() |
NS | $22.10 | +344.91% | +229.32% | +115.59 | 0 Comment | |
zoehendricks | < 20 | 3/24/2008 |
![]() |
NS | $22.36 | +339.83% | +227.46% | +112.37 | 0 Comment | |
anitaS83 | < 20 | 3/24/2008 |
![]() |
NS | $22.37 | +339.64% | +227.66% | +111.98 | 0 Comment | |
LazyTimeMoney | 69.31 | 3/25/2008 |
![]() |
NS | $22.83 | +330.78% | +228.42% | +102.36 | 0 Comment | |
marvin1234 | < 20 |
|
![]() |
3M | $22.58 | +335.45% | +233.14% | +102.31 | 1 Comment | |
televester | 80.47 | 3/17/2008 |
![]() |
NS | $21.66 | +354.05% | +252.61% | +101.44 | 0 Comment | |
Vend01 | < 20 | 3/14/2008 |
![]() |
1Y | $22.67 | +333.72% | +236.14% | +97.58 | 1 Comment | |
eatpb | < 20 | 3/14/2008 |
![]() |
3Y | $22.22 | +342.61% | +245.80% | +96.81 | 0 Comment | |
coach1937 | < 20 | 3/12/2008 |
![]() |
NS | $22.89 | +329.65% | +235.78% | +93.86 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.